患有晚期肝细胞癌受试者的治疗P1设备 (TARGET-HCC)
治疗肝癌晚期癌(HCC)患者的治疗P1设备,他们失败了第一线和第二线治疗
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are:
- will the TheraBionic P1 device affect overall survival in advance HCC
- the long term safety and tolerability of the TheraBionic P1 device
- assessment of how the disease responded to the TheraBionic P1 device
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Anthony F Shields, M.D.
- 电话号码:313-576-8735
- 邮箱:shieldsa@karmanos.org
学习地点
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 招聘中
- University of Michigan
-
接触:
- Vaibhav Sahai, MD
- 电话号码:(734) 232-6138
- 邮箱:vsahai@med.umich.edu
-
Bay City、Michigan、美国、48706
- 招聘中
- Karmanos Cancer Institute at McLaren Bay Region
-
接触:
- 电话号码:1-989-667-2370
-
Detroit、Michigan、美国、48201
- 招聘中
- Karmanos Cancer Institute
-
接触:
- Anthonly F Shields, M.D.
- 电话号码:313-576-8735
- 邮箱:shieldsa@karmanos.org
-
Flint、Michigan、美国、48532
- 招聘中
- Karmanos Cancer Institute at McLaren Flint
-
接触:
- 电话号码:1-810-342-3800
-
Lansing、Michigan、美国、48910
- 招聘中
- Karmanos Cancer Institute at McLaren Greater Lansing
-
接触:
- 电话号码:1-517-975-9500
-
Lapeer、Michigan、美国、48446
- 招聘中
- Karmanos Cancer Institute at McLaren Lapeer Region
-
接触:
- 电话号码:810-667-4994
-
Mount Pleasant、Michigan、美国、48858
- 招聘中
- Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center
-
接触:
- 电话号码:1-989-772-6811
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- University of Texas M.D. Anderson Cancer Center
-
接触:
- Kim Ross
- 电话号码:713-794-1623
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients with advanced hepatocellular carcinoma (HCC) (defined as a liver tumor not eligible for local therapies given the extent of disease or a livor tumor that recurred after local therapy)
- Patients who have failed at least two lines of therapy* or who are no longer eligible for any line of standard therapy or who are intolerant to at least two lines of therapy.
- Patients with evaluable disease
- Patients must be ≥ 22 years old and must be able to understand and sign an informed consent.
- Female patients of childbearing potential and their partners and male patients must agree to use adequate contraception during the period of study treatment.
- Patients with a life expectancy of at least 3 months
Exclusion Criteria:
- Patients with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
- Patients taking any other investigational drugs
- Patients with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of the device
- Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is discontinued to prior to treatment on study. Patients must agree to abstain from using calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels for the duration of treatment on study.
- Patients who are breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued.
- Patients that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device for the prescribed period and frequency (three 60-minute treatments in the morning, middle of the day, and evening)
- Patients with a known severe (e.g., anaphylactic) allergy to nickel
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:TheraBionic P1 device
Self administered Amplitude-modulated electromagnetic fields three times daily |
Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival
大体时间:From start of treatment until death, up to 24 months
|
Overall survival assessment will be recorded in days and will represent the period starting at the date of treatment initiation and finishing at the date of patient death from any cause. Living patients at the time of analysis will have the date of last contact (consultation visit or phone contact) used to define overall survival |
From start of treatment until death, up to 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PROMIS Measures of Pain Interference
大体时间:From Start of Treatment to the end of treatment up to 12 months
|
National Institutes of Health Patient Reported Outcome Measurement Information System (PROMIS) measures of Pain Interference short form 4a. PROMIS scores can range from 0 to 100; scales are calibrated using a T-score metric with a mean of 50 and standard deviation of 10. A higher score indicates more pain interference (poorer health). 4 items |
From Start of Treatment to the end of treatment up to 12 months
|
|
Patient-reported outcomes (PRO)
大体时间:From Start of Treatment to the end of treatment up to 12 months
|
Patient-reported outcomes (PRO) measures will assess the trajectory of patient rated tolerability of treatment (Functional Assessment of Cancer Therapy items regarding bother of side effects, one item), patient-rated symptomatic adverse events (11 Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events item library items) |
From Start of Treatment to the end of treatment up to 12 months
|
|
PROMIS Measures of Pain Intensity
大体时间:From Start of Treatment to the end of treatment up to 12 months
|
NIH Patient Reported Outcome Measurement Information System (PROMIS) measures of Pain Intensity short form 1a. PROMIS scores can range from 0 to 100; scales are calibrated using a T-score metric with a mean of 50 and standard deviation of 10. A higher score indicates more pain intensity (poorer health). 1 item |
From Start of Treatment to the end of treatment up to 12 months
|
|
ECOG Performance Status
大体时间:From Start of Treatment to the end of treatment up to 12 months
|
(ECOG)Eastern Cooperative Oncology Group performance status scale to measure functional status and ability to carry out activities of daily living. A system used to assess how a patient's cancer or other serious illness affects their daily living abilities. It's a 6-point scale (0-5) where lower scores indicate better function and higher scores indicate more limitations |
From Start of Treatment to the end of treatment up to 12 months
|
|
Disease Control Rate
大体时间:From enrollment up to 6 months
|
Disease control will be defined as the percentage of patients who are alive and have documented response status of complete response (CR), partial response (PR) or stable disease (SD) at 4 months and 6 months from the date of enrollment. |
From enrollment up to 6 months
|
|
Duration of overall response
大体时间:From start of treatment up to 24 months
|
Measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded on study). The duration of overall complete response is measured from the time measurement criteria are first met for CR until the first date that recurrent disease is objectively documented. Duration of stable disease: Stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started |
From start of treatment up to 24 months
|
|
Time to Progression (TTP)
大体时间:Start of treatment to death from any cause up to 24 months
|
Time-to-radiological progression assessment will be recorded in days and will represent the period starting at the date of treatment initiation and finishing at the date of radiological assessment documenting tumor progression. Patients who initiate post-study anticancer therapy or die without documented progression will be censored at that time point. |
Start of treatment to death from any cause up to 24 months
|
|
Progression-free survival (PFS)
大体时间:Start of treatment to progression of disease, last follow-up on study or death, whichever comes first up to 24 months
|
Progression-free survival assessment will be recorded in days and will represent the period starting at the date of treatment initiation and finishing at the later of the date of documentation of radiologic tumor progression, date of last follow-up on study treatment or death, whichever comes first. Patients who initiate post-study antitumor therapy prior to radiologic progression will be censored for PFS at that date. |
Start of treatment to progression of disease, last follow-up on study or death, whichever comes first up to 24 months
|
|
PROMIS Measures of Physical Function
大体时间:From Start of Treatment to the end of treatment up to 12 months
|
National Institutes of Health Patient Reported Outcome Measurement Information System (PROMIS) measures of physical function short form 4a. PROMIS scores can range from 0 to 100; scales are calibrated using a T-score metric with a mean of 50 and standard deviation of 10. A higher score indicates less physical function (poorer health). 4 items |
From Start of Treatment to the end of treatment up to 12 months
|
合作者和调查者
合作者
调查人员
- 首席研究员:Anthony F Shields, M.D.、Wayne State University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2024-074
- TR79005KCI00019 (其他赠款/资助编号:U Can-Cer Vive)
- AM-001 (其他标识符:TheraBionic)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.